Pharmacological studies on a cholinergic inhibition in the cerebral cortex.
D000109:Acetylcholine / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D002540:Cerebral Cortex / Q000187:drug effects*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D004491:Edrophonium / Q000494:pharmacology; D005703:Gallamine Triethiodide / Q000494:pharmacology; D007031:Hypothalamus / Q000187:drug effects; D009388:Neostigmine / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects*; D010277:Parasympathomimetics / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology; D011712:Pyramidal Tracts / Q000187:drug effects; D012601:Scopolamine / Q000494:pharmacology; D011984:Sensory Receptor Cells / Q000187:drug effects* / Q000502:physiology; D013331:Strychnine / Q000494:pharmacology; D013997:Time Factors; D014403:Tubocurarine / Q000494:pharmacology
D002800:Cholinesterase Inhibitors; D010277:Parasympathomimetics; D009388:Neostigmine; D004491:Edrophonium; D001285:Atropine; D010830:Physostigmine; D012601:Scopolamine; D013331:Strychnine; D000109:Acetylcholine; D005703:Gallamine Triethiodide; D014403:Tubocurarine